Ipsogen grants LabCorp non-exclusive rights, for the US territory, to offer an assay for the molecular classification and the diagnosis of a group of leukemias caused by Jak2 gene variations
Ipsogen, a provider of molecular diagnostic tests for the disease management of cancer patients, has signed an agreement with Laboratory Corporation of America under which LabCorp will offer a Jak2 molecular diagnostic assay in the USA.
The test is based on mutations in the Jak2 gene, to which Ipsogen has worldwide exclusive intellectual property rights.
A high proportion of patients with myeloproliferative disorders (MPD; polycythemia vera, essential thrombocythemia, idiopathic myelofibrosis) carry a dominant gain-of-function V617F mutation in the JH2 kinase-like domain of Jak2.
This pioneering work published in a 2005 issue of Nature by the Inserm team of Vainchenker (Institut Gustave Roussy, Paris) provides a breakthrough progress for the molecular classification and the diagnosis of myeloproliferative disorders.
The license allows LabCorp to provide the Jak2 mutation assay through its various Clia-registered laboratories throughout the USA.
"This agreement with LabCorp, the first US-based reference laboratory to enter our licensing program, will help Ipsogen to establish its unique molecular diagnostic solutions in the field of blood-based cancers," said Vincent Fert, president and CEO of Ipsogen.
"We are pleased that one of the leading suppliers of diagnostic services recognises the medical value of Jak2 mutation analysis, illustrating the potential of molecular diagnostic to better diagnose and define diseases, and to offer new personalised treatment approaches".
